1. Academic Validation
  2. FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients

FAPI-74 PET/CT Using Either 18F-AlF or Cold-Kit 68Ga Labeling: Biodistribution, Radiation Dosimetry, and Tumor Delineation in Lung Cancer Patients

  • J Nucl Med. 2021 Feb;62(2):201-207. doi: 10.2967/jnumed.120.245084.
Frederik L Giesel 1 Sebastian Adeberg 2 3 4 5 Mustafa Syed 2 4 Thomas Lindner 1 Luis David Jiménez-Franco 6 Eleni Mavriopoulou 1 Fabian Staudinger 1 Eric Tonndorf-Martini 2 4 Sebastian Regnery 2 4 Stefan Rieken 2 5 7 Rami El Shafie 2 5 Manuel Röhrich 1 Paul Flechsig 1 Andreas Kluge 6 Annette Altmann 1 Jürgen Debus 2 3 4 5 Uwe Haberkorn 8 9 Clemens Kratochwil 1
Affiliations

Affiliations

  • 1 Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany.
  • 2 Heidelberg Institute of Radiation Oncology, Heidelberg, Germany.
  • 3 Heidelberg Ion-Beam Therapy Center, Heidelberg, Germany.
  • 4 Department of Radiation Oncology, University Hospital Heidelberg, Heidelberg, Germany.
  • 5 Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center, Heidelberg, Germany.
  • 6 ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH, Dresden, Germany.
  • 7 Department of Radiation Oncology, University Hospital Göttingen, Göttingen, Germany; and.
  • 8 Department of Nuclear Medicine, University Hospital Heidelberg, Heidelberg, Germany uwe.haberkorn@med.uni-heidelberg.de.
  • 9 Clinical Cooperation Unit Nuclear Medicine, German Cancer Research Center, Heidelberg, Germany.
Abstract

68Ga-fibroblast activation protein inhibitors (FAPIs) 2, 4, and 46 have already been proposed as promising PET tracers. However, the short half-life of 68Ga (68 min) creates problems with manufacture and delivery. 18F (half-life, 110 min) labeling would result in a more practical large-scale production, and a cold-kit formulation would improve the spontaneous availability. The NOTA chelator ligand FAPI-74 can be labeled with both 18F-AlF and 68Ga. Here, we describe the in vivo evaluation of 18F-FAPI-74 and a proof of mechanism for 68Ga-FAPI-74 labeled at ambient temperature. Methods: In 10 patients with lung Cancer, PET scans were acquired at 10 min, 1 h, and 3 h after administration of 259 ± 26 MBq of 18F-FAPI-74. Physiologic biodistribution and tumor uptake were semiquantitatively evaluated on the basis of SUV at each time point. Absorbed doses were evaluated using OLINDA/EXM, version 1.1, and QDOSE dosimetry software with the dose calculator IDAC-Dose, version 2.1. Identical methods were used to evaluate one examination after injection of 263 MBq of 68Ga-FAPI-74. Results: The highest contrast was achieved in primary tumors, lymph nodes, and distant metastases at 1 h after injection, with an SUVmax of more than 10. The effective dose per a 100-MBq administered activity of 18F-FAPI-74 was 1.4 ± 0.2 mSv, and for 68Ga-FAPI-74 it was 1.6 mSv. Thus, the radiation burden of a diagnostic 18F-FAPI-74 PET scan is even lower than that of PET scans with 18F-FDG and other 18F tracers; 68Ga-FAPI-74 is comparable to other 68Ga ligands. FAPI PET/CT supported target volume definition for guiding radiotherapy. Conclusion: The high contrast and low radiation burden of FAPI-74 PET/CT favor multiple clinical applications. Centralized large-scale production of 18F-FAPI-74 or decentralized cold-kit labeling of 68Ga-FAPI-74 allows flexible routine use.

Keywords

FAPI PET/CT; cancer-associated fibroblasts; cold kit; lung cancer; radiation dosimetry.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-147173
    99.84%, PET示踪剂
    FAP